IDEAYA Biosciences, Inc. (IDYA) Stock
IDYA has an Alpha Score of 33 out of 100 (poor), computed on Nov 11, 2026 from 2 of 4 sub-scores. 3 of the hedge funds AlphaScala tracks reported IDYA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $11.20M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
What is IDYA's Alpha Score?
How it works →Alpha Score of 33 reflects weak overall profile with weak momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 11, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own IDYA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 300K | $11.20M | -56% |
| D.E. Shaw David Shaw | 21K | $773.8K | NEW |
| Millennium Management Israel Englander | 11K | $391.3K | -95% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are IDEAYA Biosciences, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 6, 26 | Hata Yujiro S | President and CEO | SELL | 25.5K | $955K |
| Oct 6, 26 | Hata Yujiro S | President and CEO | SELL | 800 | $31K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are IDYA's key statistics?
Key statistics as of Nov 3, 2026
How does IDYA's valuation compare with the Healthcare sector?
| Metric | IDYA | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -74.75% | 3.60% | 175 |
| Return on equity | -16.47% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
IDYA price chart
Powered by TradingViewWhat does IDEAYA Biosciences, Inc. do?
Ideaya Biosciences Inc. is a precision medicine oncology company that discovers and develops targeted therapeutics for patient populations identified through molecular diagnostics. Its pipeline features IDE196, a protein kinase C inhibitor in Phase 2/3 clinical trials for cancers with GNAQ or GNA11 mutations; IDE397, a methionine adenosyltransferase 2a inhibitor in Phase 2 for solid tumors with MTAP deletions like non-small cell lung cancer and urothelial cancer; IDE849, a DLL3 antibody drug conjugate in Phase 1 for small cell lung cancer and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor in Phase 1 for high microsatellite instability tumors; IDE161, a poly ADP-ribose glycohydrolase inhibitor in Phase 1/2 for homologous recombination deficiency tumors; and IDE705, a Poly Theta Helicase inhibitor in Phase 1 for BRCA-mutated tumors. The company also advances preclinical programs such as IDE892, an MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 bispecific antibody drug conjugate; and IDE251, a KAT6/7 inhibitor, alongside research platforms like DECIPHER for synthetic lethality and INQUIRE for drug discovery enhancement. Ideaya Biosciences Inc. maintains strategic alliances with partners including GlaxoSmithKline, Pfizer, Gilead Sciences, Merck, and others. Incorporated in 2015 and headquartered in South San Francisco, California, it plays a key role in advancing precision oncology therapies.